Full-Time

Senior Healthcare Compliance Director

Healthcare Compliance

Posted on 5/9/2026

Intellia Therapeutics

Intellia Therapeutics

201-500 employees

CRISPR-Cas9 genome-editing therapeutics developer

Compensation Overview

$267.4k - $326.9k/yr

+ Bonus + Equity Grants

Cambridge, MA, USA

Hybrid

Category
Legal & Compliance (1)
Requirements
  • Unimpeachable integrity, good judgment, assertiveness, an approachable demeanor, and the ability to elicit the respect and trust of employees
  • Deep knowledge of pharmaceutical laws, regulations and industry guidance pertaining to the commercialization of biopharmaceutical products
  • Broad experience in the biopharmaceutical industry and understanding of key commercial activities, including sales and marketing, health care professional and patient engagements and interactions, product distribution, market access, and patient support services; experience in rare disease is a plus
  • Self-starter who can lead projects independently from inception to completion with minimal supervision
  • Excellent communications skills, both verbal and written, including the ability to effectively lead presentations and deliver trainings
  • Exceptional organizational skills and attention to detail
  • Solid track record of building strong working relationships in a cross-functional matrix environment, working with different personality types, and managing conflict
  • Strong work ethic, positive outlook, commitment to legal and business teams
  • Collaborative style; team player
  • Prolonged periods of sitting at a desk and working on a computer
  • B.A./B.S. degree required, JD strongly preferred
  • 10+ years of healthcare compliance and/or other related experience in biotech/pharmaceutical organization
  • Prolonged periods of sitting at a desk and working on a computer
Responsibilities
  • Build and manage key elements of Intellia’s Healthcare Compliance Program in accordance with laws and industry guidance, including OIG Guidance for Pharmaceutical Manufacturers, the PhRMA Code on Interactions with Healthcare Professionals, the Food Drug and Cosmetic Act, the Physician Payments Sunshine Act, and other pharmaceutical laws and regulations
  • Serve as a primary business partner helping Commercial and Medical leadership execute their product launch objectives while managing compliance risk
  • Develop, implement, and oversee healthcare compliance policies and procedures prioritized by ongoing risk assessments and commercial infrastructure buildout
  • Curate the healthcare compliance training syllabus and develop and deliver virtual and live trainings tailored to Intellia’s business
  • Develop and implement a risk-based monitoring plan for essential policies and procedures and partner cross-functionally to facilitate auditable record-keeping
  • Partner cross-functionally to establish Intellia’s systems and processes for aggregate spend reporting
  • Work closely with Legal colleagues and the Head of Healthcare Compliance to evaluate compliance risks and resolve compliance matters
  • Report to and advise Intellia’s Risk Oversight and Compliance Committee on accomplishments, challenges, and the overall effectiveness of Intellia’s Healthcare Compliance Program
  • Maintain understanding of Intellia’s business objectives and activities and keep abreast of industry and enforcement trends that may impact Intellia’s operations and Healthcare Compliance Program
  • Promote Intellia’s values and establish “Compliance by Design” principles as integral to achieving business objectives and improving processes and decision-making
  • As part of a growing and evolving business, this role will have the opportunity for a diverse workload, visibility as a leader, and continued development opportunities
Intellia Therapeutics

Intellia Therapeutics

View

Intellia Therapeutics develops CRISPR-Cas9 genome editing therapies to treat severe genetic diseases. Its work centers on using CRISPR to edit genes and delivering the editing tools to the right cells with a modular lipid nanoparticle system, aiming to create treatments that can be given to patients and move through clinical trials toward market. The company earns revenue through R&D collaborations, licensing, and potential sales of approved therapies. Compared to others in biotech, Intellia emphasizes in vivo gene editing using a distinctive lipid nanoparticle delivery approach and active partnerships to advance candidates. Its goal is to bring safe, effective genome-editing treatments to patients while building value through collaborations and licensing.

Company Size

201-500

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • Rolling BLA submission underway; potential FDA approval and 2027 commercial launch.
  • ARK Invest acquired $43M stake signaling institutional confidence in CRISPR gene-editing platform.
  • $605M cash runway supports operations through H2 2027 including anticipated US launch.

What critics are saying

  • Nex-z patient death from liver toxicity in December 2025 threatens regulatory credibility.
  • FDA clinical hold on MAGNITUDE remains unresolved; MAGNITUDE-2 faces enrollment restrictions.
  • Lonvo-z BLA rejection or delay to 2028 exhausts cash runway by mid-2027.

What makes Intellia Therapeutics unique

  • First in vivo CRISPR therapy with 87% attack reduction versus placebo in Phase 3.
  • One-time infusion treatment contrasts with twice-weekly injections or daily pills for HAE.
  • Exclusive comprehensive CRISPR-Cas9 intellectual property platform for therapeutic applications.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Intellia Therapeutics who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Flexible Work Hours

Remote Work Options

Paid Vacation

Paid Sick Leave

Paid Holidays

Sabbatical Leave

Hybrid Work Options

Stock Options

Company Equity

401(k) Retirement Plan

Wellness Program

Mental Health Support

Gym Membership

Phone/Internet Stipend

Home Office Stipend

Professional Development Budget

Conference Attendance Budget

Tuition Reimbursement

Professional Certification Support

Mentorship Program

Family Planning Benefits

Fertility Treatment Support

Parenting Leave

Adoption Assistance

Childcare Support

Elder Care Support

Commuter Benefits

Meal Benefits

Employee Discounts

Company Social Events

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-4%

2 year growth

-2%
Yahoo Finance
Feb 28th, 2026
Intellia Therapeutics reports $605M cash reserves, expects runway into 2027

Intellia Therapeutics has reported its fiscal Q4 and full year 2025 financial results, with cash, cash equivalents and marketable securities of $605.1 million as of 31 December 2025, down from $861.7 million in the prior year. The company expects these funds to support operations into the second half of 2027, including through the anticipated US commercial launch of lonvo-z for hereditary angioedema. Collaboration revenue for Q4 reached $23.0 million, up from $12.9 million year-on-year, driven by $9.0 million from the termination of its licence agreement with SparingVision and increased cost reimbursements from its Regeneron collaboration. Research and development expenses fell to $88.7 million from $116.9 million in the prior year period. The clinical-stage company develops genome editing therapeutics using CRISPR/Cas9 technology.

Yahoo Finance
Feb 28th, 2026
Intellia completes phase 3 enrollment for lonvo-z, aims for mid-2026 data with $605M cash

Intellia Therapeutics has completed enrolment in its phase 3 HAELO trial for lonvo-z, expecting top-line data by mid-2026 and planning a biologics licence application submission in the second half of 2026. The company is preparing for a potential one-time hereditary angioedema treatment launch. The FDA placed Intellia's in vivo ATTR programme (nex-z) on clinical hold following liver enzyme events. The hold was lifted for the MAGNITUDE-2 polyneuropathy study with enhanced monitoring requirements, whilst the cardiomyopathy study remains on hold pending review. Intellia reported $605.1 million in cash as of 31 December 2025, sufficient to fund operations into the second half of 2027. The company posted a reduced fourth-quarter net loss of $95.8 million alongside higher collaboration revenue.

The Associated Press
Feb 26th, 2026
Intellia's lonvo-z for HAE targets mid-2026 Phase 3 data, BLA filing and 2027 US launch

Intellia Therapeutics reported fourth-quarter 2025 financial results and provided updates on its CRISPR gene-editing programmes. The company ended 2025 with approximately $605 million in cash, expected to fund operations into the second half of 2027. For lonvoguran ziclumeran (lonvo-z) treating hereditary angioedema, Intellia expects Phase 3 HAELO clinical data by mid-2026, with a biologics licence application submission in the second half of 2026 and anticipated US launch in the first half of 2027. The company completed dosing of 80 patients in September 2025. For nexiguran ziclumeran (nex-z) treating ATTR amyloidosis, Intellia is reactivating global sites for the MAGNITUDE-2 Phase 3 trial following the FDA's January 2026 clinical hold lift, with enrollment completion expected in the second half of 2026. Engagement continues regarding the clinical hold on the MAGNITUDE trial.

Yahoo Finance
Jan 20th, 2026
Intellia Therapeutics shares surge 35% in a month but trade 95% below DCF valuation

Intellia Therapeutics shares have surged 35.4% over the past month and 35.7% year-to-date, trading around $12.50. However, the stock scores just 2 out of 6 on valuation checks, suggesting the market prices it favourably on only a couple of basic tests. A discounted cash flow analysis estimates the company's intrinsic value at $233.98 per share, implying the stock is 94.7% undervalued at current levels. The model projects Intellia moving from negative free cash flow of $420 million in the latest twelve months to positive cash flow of approximately $370 million by 2030. Despite recent gains, the stock has posted weak longer-term returns, declining 65.2% over three years and 82.5% over five years.

AD HOC NEWS Portal Aktiengesellschaft
Dec 31st, 2025
ARK Invest buys $1.33M in Intellia Therapeutics as gene-editing stock trades near lows

ARK Invest, led by Cathie Wood, has purchased approximately 145,153 shares of Intellia Therapeutics worth $1.33 million, significantly increasing its stake in the gene-editing company. The acquisition comes as the stock trades near multi-year lows between $9.00 and $9.60, funded partly through reducing positions in Roku and Shopify. The purchase contrasts sharply with Intellia's current challenges. The FDA imposed clinical holds on two key CRISPR programmes in Q4 following safety data showing significant liver damage in trial participants. The company reported a Q3 2025 net loss of $101.3 million, improved from $135.7 million the previous year. With no approved products generating revenue and regulatory uncertainty persisting, the stock remains highly speculative, valued at just over $1 billion market capitalisation.